In silico screening of potent bioactive compounds from honey bee products against COVID-19 target enzymes

Moataz A. Shaldam¹, Galal Yahya²,³, Nashwa H. Mohamed⁴, Mohamed M. Abdel-Daim⁵,⁶, Yahya Al Naggar⁵,⁶*

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafr EL Sheikh University, Kafir El Sheikh, 33516, Egypt.
²Microbiology and Immunology Department, Faculty of Pharmacy, Zagazig University 44519, Al Sharqia, Egypt.
³Department of Molecular Genetics, Faculty of Biology, Technical University of Kaiserslautern, Paul-Ehrlich Str. 24, Kaiserslautern 67663, Germany.
⁴Hospitals of Zagazig University, Al Sharqia, Egypt.
⁵Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
⁶Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt
⁷Zoology Department, Faculty of Science, Tanta University 31527, Tanta, Egypt.
⁸General Zoology, Institute for Biology, Martin Luther University Halle-Wittenberg, Hoher weg 8, 06120 Halle (Saale), Germany.

*Correspondence:

Dr Y. Al Naggar, General Zoology, Institute for Biology, Martin Luther University Halle-Wittenberg, Hoher Weg 8, 06120 Halle (Saale), Germany
E-mail: yehia.elnagar@science.tanta.edu.eg
Telephone: +49-345 5526511
FAX: +49-345 5527428
Abstract
From the early days of the COVID-19 pandemic, side by side to immense investigates to design specific drugs or to develop a potential vaccine for the novel coronavirus. Myriads of FDA approved drugs are massively repurposed for COVID-19 treatment based on molecular docking of selected protein targets that play vital for the replication cycle of the virus. Honey bee products are well known of their nutritional values and medicinal effects. Antimicrobial activity of bee products and natural honey have been documented in several clinical studies and was considered a good alternative for antiviral medications to treat some viral infections. Bee products contain bioactive compounds in the form of a collection of phenolic acids, flavonoids and terpenes of natural origin. We revealed by molecular docking the profound binding affinity of 14 selected phenolics and terpenes present in honey and propolis (bees glue) against the main protease (M<sup>pro</sup>) and RNA dependent RNA polymerase (RdRp) enzymes of the novel 2019-nCoV coronavirus. Of these compounds, p-coumaric acid, ellagic acid, kaemferol and quercetin has the strongest interaction with the 2019-nCoV target enzymes, and they may be considered as an effective 2019-nCoV inhibitors.

Key words: COVID-19, Honey Bee products, Phenolic compounds, Molecular docking, Drug repurposing, Natural products.
Introduction

Owing to increased global travel and rapid urbanization, viruses are responsible for a variety of human pathologies. In December 2019, several cases of pneumonia of unknown cause were detected in Wuhan, province of Hubei in China. Most patients shared similar symptoms of dry cough, fever, and fatigue, then they developed into dyspnea quickly, ending up with acute respiratory distress syndrome (ARDS) (Chen et al. 2020, Chan et al. 2020, Zhu et al. 2020, Huang et al. 2020, Zhou et al. 2020). By whole-genome sequencing of samples obtained from lower respiratory tract of the patients, a new coronavirus was detected, further investigations revealed that the novel corona virus is different from severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) coronavirus (Zhu et al. 2020). On February 11, 2020, World Health Organization (WHO) named it coronavirus disease-19 (COVID-19) officially, then declared it a pandemic on March 12, 2020 (World Health Organization 2020).

As of June 06, 2020, the cumulative number of cases diagnosed with COVID-19 in the world was more than 7 million, while the cumulative number of cured cases was more than 3,4 million whereas more than 400,000 cases died (2020b). As a direct effect of the outbreak of COVID-19, more than 160 countries are fighting to combat the spread of COVID-19 and taking protective measures to save their citizens from the pandemic, at the same time research institutes, drug corporations, biotechnology institutes, research groups in different universities all over the world are racing to develop effective drugs or potential vaccines for COVI-19. Internationally by June 2020, there are over 159 vaccine candidates (Sharpe et al. 2020, Thanh Le et al. 2020) and more than 300 potential therapies for COVID-19 disease in various stages of preclinical or clinical research (Pooladanda et al. 2020, Hachfi and Ben Lasfar 2020, 2020a, Mullard 2020).
As a fast track to save time needed for safety and approval studies, researchers started to massively repurpose already FDA approved drugs for Covid19 treatment (Kandeel and Al-Nazawi 2020, Harrison 2020). Computational based techniques like molecular modeling and virtual screening represent magic tools to understand the molecular aspects of protein ligand interactions during rational drug design process (Murgueitio et al. 2012). Virtual screening has been encountered in structure-based drug design against emerging and fatal diseases of viral origin. (Sirois et al. 2004, Elhefnawi et al. 2012, Raj and Varadwaj 2016, Zhou et al. 2008, Plewczyński et al. 2007).

Based on their crucial role in the life cycle of SARS CoV2, COVID-19 RNA-dependent RNA polymerase (RdRp) (Gao et al. 2020) and the main protease (Mpro) (Jin et al. 2020) have been extensively docked to design or distinguish effective drugs for COVID-19. Bioactive compounds from natural origin are currently screened by molecular docking to in silico test their affinity to molecular targets of COVID-19 taking the advantage that natural product are free from toxic or side effects (Mani et al. 2020, Sayed et al. 2020, Gurung et al. 2020). Of the natural products that recently acquired increasing prophylactic importance to combat viral infections in general and COVID-19 in particular are honey bee products.

Honey bees are the “Golden insects” that produce honey and other vital honeybee products. Their products have a long history in medicine. All cultures have traditions of folk medicine which include the use of honey bee products, i.e. honey, bee pollen, propolis, royal jelly, beeswax, and bee venom. It was found that these products display anti-inflammatory, antibacterial, anti-fungal, anti-viral, antioxidant activities and neuroprotection (Pasupuleti et al. 2017, El-Seedi et al. 2020). Recently, honey has been proposed as a potential compatible antiseptic prophylaxis to help protect against the COVID-19 based on biocidal effect of
hydrogen peroxide that produced in most traditional honeys (Al Naggar et al. 2020, in press). However, the potential bioactive compounds derived from honey and other bee products are not identified yet and deserve more attention.

Therefore, the aim of the present study is to perform deep virtual screening via molecular docking to test binding affinity of various selected bioactive compounds such as terpenes and flavonoids of honey and propolis as inhibitors against COVID-19 essential enzymes: RNA-dependent RNA polymerase and the main protease.

**Docking methodology**

The crystal structure of COVID-19 RNA-dependent RNA polymerase (RdRp) (PDB code: 6M71) (Gao et al. 2020) and the main protease (Mpro) (PDB code: 6LU7) (Jin et al. 2020) were retrieved from Protein Data Bank. This study was carried out on 14 compounds (Fig. 1) from honey and propolis into the receptor active site using AutoDock Vina (Trott and Olson 2010). Ligand structures were drawn into Marvin Sketch V19.12 (2020c) and the most energetically favored conformer was exported as (*.pdb) file format. AutoDockTools package (Morris et al. 2009) was used to assign Gasteiger atomic partial charges and all the rotatable bonds in ligands were set to be flexible. For receptor preparation, all water molecules were removed, the co-crystalized ligand was removed, Gasteiger atomic partial charges were assigned and all receptors and ligands were converted to the PDBQT format using AutoDockTools package for docking process. In the AutoDock Vina configuration files, the parameter num modes was set to 10 and exhaustiveness to 14. The grid boxes of center (x= 118.23, y= 103.32 and z= 118.37) with size (x=17, y=25, z=17) for the RNA-dependent RNA polymerase and center (x= -10.71, y= 12.41 and z= 68.83) with size (x=16, y=18, z=16) for the main protease were used to define the active site. AutoDock Vina was executed. Pymol (2020d) was used for
3D visualization and the 2D schematic presentation was generated using LigPlot+ V1.4.5 (Laskowski and Swindells 2011).

**Results and discussion**

Honey bee products contain minor amounts of flavonoids, phenols, phenolic acids, carotenoids and terpenes (Fig. 1). These phenolic compounds and terpenes found to possess variable medicinal effects including wound healing, antioxidant, antimicrobial, antiviral, anti-inflammatory, cardioprotective, and neuroprotective activities (Biesalski et al. 2009; Küçük et al. 2007; El-Seedi et al. 2020). Recently many drugs that are designed and clinically implicated for other medicinal aspects have been repurposed for COVID-19 treatment (Kandeel and Al-Nazawi 2020, Oliveira et al. 2020). Therefore, honey bee products represent a natural pharmacy that harbor collection of remedies of broad medicinal effects and might be repurposed against COVID-19.

Bioinformatics is one of the most important and innovative approaches to design new drugs (Li et al., 2020). Due to the high cost of clinical and laboratory trials, the time consuming and the possibility of error, different bioinformatics techniques are nowadays used in the design of new drugs (Shaghaghi, 2020). In the current study, computational docking was implemented to predict the binding mode of 14 compounds from honey and propolis with two different targets from COVID-19; RNA-dependent RNA polymerase (RdRp) (PDB code: 6M71) and the main protease (M^{pro}) (PDB code: 6LU7). We revealed that the bioactive compounds; ellagic acid, hesperetin, and kaempferol are the most promising compounds on COVID-19 RdRp while artemillin C, ellagic acid, hesperetin, kaempferol and quercetin were the most active on the main protease (Mpro). The binding scores for each compound into the two targets are shown in Table 1. The binding mode for ellagic acid to COVID-19 RdRb site was attributed to H-bond
interaction with Gly808, pro809, His816, Thr817 and Tyr 831, while amino acid residues Trp617, Asp760 and Asp761 are positioned at distance of H-bond with hesperetin, and also kaempferol interacts with Glu811 and Asp761 by H-bond. Furthermore, the aromatic ring system of ellagic acid, hesperetin and kaempferol make π-ion hydrophobic interaction with Lys798 (Fig. 2). We spot the light on the high affinity bioactive compounds like phenolic and flavonoids of honey as potent inhibitors of viral replication.

From the docking of all identified compounds into the active site of SARS-CoV-2 main protease (M\textsuperscript{pro}) in the current study, artemillin C showed H-bond interaction with Cys145, Arg188, Thr190 and Gln192, while amino acid residues His41, Gly143 and Arg188 are positioned at distance of H-bond with ellagic acid (Fig. 3). In addition, hesperetin interacts with Gly143 by H-bond while amino acid residues Tyr54, Leu141, Ser144, Asp 187 and Gln189 are positioned at distance of H-bond with kaempferol, and also quercetin makes H-bond with Tyr54, Leu141, Ser144, His163, and Gln189. Furthermore, the aromatic ring system of artemillin C, ellagic acid, hesperetin, kaempferol and quercetin make π-ion hydrophobic interaction with either Met165 or Glu166 (Fig. 4). Taken together we propose phenolic acids and flavonoids from honey bee products as potential inhibitor of the main protease of SARS-CoV-2 (COVID-19).

In the same context, our promising candidates like \textit{p}-coumaric acid, ellagic acid, kaemferol and quercetin were previously found to have potential antiviral activity against the common cold human rhinovirus which is RNA virus like SARS-CoV2. Surprisingly the mentioned bioactive compounds were suggested in the same study to block or reduce the viral entry into the cells to protect the cells from the virus cytopathic effects and subside virus replication (Kwon et al. 2019), supporting our virtual screening. Moreover, quercetin and its derivatives were previously confirmed to inhibit the SARS-CoV proteases (Nguyen et al. 2012).
and other coronaviruses including SARS-CoV proteases (3CLpro and PLpro) as well as the Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) 3CLpro protease. Quercetin was also able to inhibit both enzymes in vitro in micromolar doses (Park et al. 2017).

Conclusions

Theoretical studies through molecular docking of collection of bioactive compounds of honey bee products against selected targets of COVID-19 including Mpro and RdRb enzymes of the 2019-nCoV virus have distinguished promising bioactive compounds of natural origin that exhibited profound binding to the respective COVID-19 targets. Among the investigated bioactive compounds derived from honey and propolis, p-coumaric acid, ellagic acid, kaemferol and quercetin are the most promising compounds on 2019-nCoV active sites (RdRb and Mpro). These potent bioactive compounds were also found to have potential antiviral activity against the common cold human rhinovirus which is RNA virus like SARS-CoV2. Taken all together and based on our theoretical studies supported by previous in vitro confirmatory studies, we recommend further in vivo investigations to assess the predicted affinity of the selected compounds against the novel coronavirus (COVID-19) target enzymes.

Acknowledgments

We wish to confirm that there are no known conflicts of interest associated with this publication, and there has been no significant financial support for this work that could have influenced its outcome. YA & GY are grateful to Alexander von Humboldt (AvH) foundation for post-doc fellowships.
Al Naggar, Yahya; Ansari, Mohamed; Giesy, John; Yahya, Galal (2020, in press). Repurposing Honey for Antiseptic Prophylaxis against Novel Coronavirus COVID-19. In *Natural Product Research*. https://www.bioworld.com/COVID19products. Accessed 11 Jun 2020

Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S, Tsoi H-W, Lo SK-F, Chan K-H, Poon VK-M, Chan W-M, Ip JD, Cai J-P, Cheng VC-C, Chen H, Hui CK-M, Yuen K-Y (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England) 395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J'a, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7

Coronavirus Update (Live): COVID-19 Virus Pandemic - Worldometer (2020b). https://www.worldometers.info/coronavirus/. Accessed 13 Jun 2020

Elhefnawi M, ElGamacy M, Fares M (2012) Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors. BMC bioinformatics 13 Suppl 17:S5. doi: 10.1186/1471-2105-13-S17-S5

El-Seedi HR, Khalifa SAM, El-Wahed AA, Gao R, Guo Z, Tahir HE, Zhao C, Du M, Farag MA, Musharraf SG, Abbas G (2020) Honeybee products: An updated review of neurological actions. Trends in Food Science & Technology 101:17–27. doi: 10.1016/j.tifs.2020.04.026

Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, Sun Q, Ming Z, Zhang L, Ge J, Zheng L, Zhang Y, Wang H, Zhu Y, Zhu C, Hu T, Hua T, Zhang B, Yang X, Li J, Yang H, Liu Z, Xu W, Guddat LW, Wang Q, Lou Z, Rao Z (2020) Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science (New York, N.Y.) 368(6492):779–782. doi: 10.1126/science.abb7498

Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM (2020) Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach. Life sciences 255:117831. doi: 10.1016/j.lfs.2020.117831

Hachfi W, Ben Lasfar N (2020) COVID-19: Main therapeutic options. La Tunisie medicale 98(4):299–303

Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nature biotechnology 38(4):379–381. doi: 10.1038/d41587-020-00003-1
novel coronavirus in Wuhan, China. The Lancet 395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. doi: 10.1038/s41586-020-2223-y

Kandeel M, Al-Nazawi M (2020) Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life sciences 251:117627. doi: 10.1016/j.lfs.2020.117627

Kwon MJ, Shin HM, Perumalsamy H, Wang X, Ahn Y-J (2019) Antiviral effects and possible mechanisms of action of constituents from Brazilian propolis and related compounds. Journal of Apicultural Research:1–13. doi: 10.1080/00218839.2019.1695715

Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal of chemical information and modeling 51(10):2778–2786. doi: 10.1021/ci200227u

Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M (2020) Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus research 284:197989. doi: 10.1016/j.virusres.2020.197989

Marvin | ChemAxon. version 19.12, by ChemAxon (2020c). https://chemaxon.com/products/marvin. Accessed 11 Jun 2020

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry 30(16):2785–2791. doi: 10.1002/jcc.21256

Mullard A (2020) Flooded by the torrent: the COVID-19 drug pipeline. Lancet (London, England) 395(10232):1245–1246. doi: 10.1016/S0140-6736(20)30894-1

Murgueitio MS, Bermudez M, Mortier J, Wolber G (2012) In silico virtual screening approaches for anti-viral drug discovery. Drug discovery today. Technologies 9(3):e219-25. doi: 10.1016/j.ddtec.2012.07.009

Nguyen TTH, Woo H-J, Kang H-K, van Nguyen D, Kim Y-M, Kim D-W, Ahn S-A, Xia Y, Kim D (2012) Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnology letters 34(5):831–838. doi: 10.1007/s10529-011-0845-8

Oliveira OV de, Rocha GB, Paluch AS, Costa LT (2020) Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. Journal of biomolecular structure & dynamics:1–10. doi: 10.1080/07391102.2020.1772885

Park J-Y, Yuk HJ, Ryu HW, Lim SH, Kim KS, Park KH, Ryu YB, Lee WS (2017) Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors. Journal of enzyme inhibition and medicinal chemistry 32(1):504–515. doi: 10.1080/14756366.2016.1265519

Pasupuleti VR, Sammugam L, Ramesh N, Gan SH (2017) Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits. Oxidative medicine and cellular longevity 2017:1259510. doi: 10.1155/2017/1259510
Plewczynski D, Hoffmann M, Grotthuss M von, Ginalska K, Rychewski L (2007) In silico prediction of SARS protease inhibitors by virtual high throughput screening. Chemical biology & drug design 69(4):269–279. doi: 10.1111/j.1747-0285.2007.00475.x

Pooladanda V, Thatikonda S, Godugu C (2020) The current understanding and potential therapeutic options to combat COVID-19. Life sciences 254:117765. doi: 10.1016/j.lfs.2020.117765

PyMOL Molecular Visualization System. Version 2.0, by Schrödinger (2020d). https://pymol.org/2/. Accessed 11 Jun 2020

Pérez AM, Khattab AR, AboulMagd AM, Hassan HM, Rateb ME, Zaid H, Abdelmohsen UR (2020) Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale. RSC Adv. 10(34):19790–19802. doi: 10.1039/D0RA04199H

Sharpe HR, Gilbride C, Allen E, Belij-Rammerstorfer S, Bissett C, Ewer K, Lambe T (2020) The early landscape of COVID-19 vaccine development in the UK and rest of the world. Immunology. doi: 10.1111/imn.13222

Sirois S, Wei D-Q, Du Q, Chou K-C (2004) Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. Journal of chemical information and computer sciences 44(3):1111–1122. doi: 10.1021/ci0304270n

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (2020) The COVID-19 vaccine development landscape. Nature reviews. Drug discovery 19(5):305–306. doi: 10.1038/d41573-020-00073-5

Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry 31(2):455–461. doi: 10.1002/jcc.21334

World Health Organization (2020) Novel Coronavirus – China. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/. Accessed 11 Jun 2020

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273. doi: 10.1038/s41586-020-2012-7

Zhou Z, Khaliq M, Suk J-E, Patkar C, Li L, Kuhn RJ, Post CB (2008) Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS chemical biology 3(12):765–775. doi: 10.1021/cb800176t

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W (2020) A Novel Coronavirus from Patients
with Pneumonia in China, 2019. The New England journal of medicine 382(8):727–733. doi: 10.1056/NEJMoa2001017
Figure legends

**Figure 1.** Chemical structure of important bioactive compounds in honey, propolis, and royal jelly.

**Figure 2.** The docking complex of (a) Ellagic acid, (b) Hesperetin and (c) Kaempferol (green) with the X-ray structure of 6M71; SARS-CoV-2 RNA-dependent RNA polymerase (left, Tint) that showed hydrogen bond (blue) interaction and 2D schematic diagram of the interaction (right).

**Figure 3.** The docking complex of (a) Artepillin C and (b) Ellagic acid (green) with the X-ray structure of 6LU7; SARS-CoV-2 main protease (M\textsuperscript{pro}) (left, Tint) that showed hydrogen bond (blue) interaction and 2D schematic diagram of the interaction (right).

**Figure 4.** The docking complex of (a) Hesperetin (b) Kaempferol and (c) Quercetin (green) with the X-ray structure of 6LU7; SARS-CoV-2 main protease (M\textsuperscript{pro}) (left, Tint) that showed hydrogen bond (blue) interaction and 2D schematic diagram of the interaction (right).
Fig. 1

2,2-Dimethyl-8-prenylchromene
4-Hydroxy-3,5-diprenyl cinnamic acid (Artepillin C)

Isocupressic acid
13C-symphoretic acid

Ellagic acid

Syringic acid
Caffeic acid phenethyl ester

p-Coumaric acid

Hesperetin
Naringenin

|          | R₁ | R₂ | R₃ |
|----------|----|----|----|
| Kaempferol| OH | H  | H  |
| Quercetin | OH | H  | OH |
| Chrysins  | H  | OCH₃| OCH₃|
Fig. 2

(a)

(b)

(c)
Fig. 3
Fig. 4
Table 1. The binding scores for each compound into the two target enzymes of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and the main protease (M\text{pro})

| Bioactive compounds                  | SARS-CoV-2 RNA-dependent RNA polymerase | SARS-CoV-2 main protease (M\text{pro}) |
|--------------------------------------|----------------------------------------|----------------------------------------|
| 2,2-Dimethyl-8-prenylchromene        | -5.6                                   | -6.8                                   |
| Artepillin C                         | -5.9                                   | -7.5                                   |
| 3-Prenyl cinnamic acid allyl ester   | -5.3                                   | -6.2                                   |
| Isocupressic acid                    | -5.8                                   | -6.4                                   |
| 13C-symphyoretic acid                | -5.7                                   | -6.9                                   |
| Ellagic acid                         | -6.4                                   | -7.5                                   |
| Syringic acid                        | -5.5                                   | -5.6                                   |
| Caffeic acid phenethyl ester         | -5.4                                   | -7.0                                   |
| p-Coumaric acid                      | -5.3                                   | -5.6                                   |
| Hesperetin                           | -6.3                                   | -7.4                                   |
| Naringenin                           | -6.0                                   | -6.5                                   |
| Kaempferol                           | -6.2                                   | -7.8                                   |
| Quercetin                            | -6.1                                   | -7.4                                   |
| Chrysain                             | -6.1                                   | -7.2                                   |